ERNA Dilution Risk Analysis: Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. (ERNA) carries a DilutionWatch dilution risk score of 84/100 — CRITICAL. This score is derived from real-time SEC filing data including active shelf registration capacity, ATM program activity, warrant overhang, estimated cash runway, and historical share count growth.

What's Driving ERNA's Score

DilutionWatch scores five dimensions of dilution risk for every ticker. For ERNA in the biotech space, the combination of capital needs and limited financing alternatives typically drives elevated scores:

• Shelf registration capacity — Active S-3 filings allow ERNA to issue shares at any time without additional SEC review. The ratio of registered-but-unissued shares to current market cap is a primary score driver.
• ATM program activity — At-The-Market programs drip-sell shares daily. 424B3 filings indicate whether an ATM is active and how aggressively it's being used.
• Warrant & convertible overhang — Outstanding warrants and convertible instruments represent future share issuance. High coverage ratios cap stock rallies and guarantee dilution when exercised.
• Cash runway estimate — biotech companies often operate at a loss. DilutionWatch estimates months of remaining cash from balance sheet data; under 6 months is a red flag.
• Historical dilution pattern — The share count history is the single most predictive metric. Consistent share count growth over 3 years indicates a company that regularly relies on equity raises.

Key Filings to Watch for ERNA

• S-3 / S-3/A — Shelf registration or amendment. Filing signals preparation for an equity offering.
• 424B3 / 424B5 — Prospectus supplement. Shares are being sold now or imminently.
• 8-K Item 1.01 — Material agreements. New convertible notes or PIPE deals appear here first.
• DEF14A — Proxy. Authorized share increases and reverse split proposals.